Bharat Parenterals Ltd says subsidiary Innoxel Lifesciences received a USFDA EIR for its Vadodara facility
- USFDA closed its assessment following an unannounced pre-approval inspection conducted April 13–20, 2026.
- The agency considered the facility ready to support commercial operations of the subject injectable product.
- This is the facility’s second EIR.
